Novartis licenses Portola's elinogrel
This article was originally published in Scrip
Executive Summary
Novartis is to pay up to $575 million for exclusive worldwide rights to Portola Pharmaceuticals' novel anti-clotting drug elinogrel (PRT060128). The drug is a P2Y12 ADP receptor antagonist and is in Phase II development in intravenous and oral formulations.